Complement deficiency — recurrent Neisseria infection workup
Terminal/alternative complement defects and meningococcal risk · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Deficiencies of the terminal complement components (C5-C9) and the alternative pathway predispose to recurrent or unusual Neisseria infections, including recurrent meningococcal disease with non-groupable strains. Identifying the defect allows targeted vaccination and antibiotic prophylaxis to prevent life-threatening infection.
Red flags
- Recurrent meningococcal disease, especially non-groupable/unusual serogroups
- Family history of recurrent Neisseria infection
- Fulminant sepsis with purpura
- Disseminated gonococcal infection without obvious risk
- Absent CH50 or AP50 on screening
Assessment
Differential diagnosis
- Terminal complement (C5-C9) deficiency
- Properdin / alternative pathway deficiency
- Early classical complement (C1-C4) deficiency (more lupus-like)
- Asplenia / hyposplenism
- Antibody deficiency (CVID / specific antibody deficiency)
Investigations
- CH50 (classical pathway) and AP50/AH50 (alternative pathway) screening — both guide the defect
- Individual complement component assays if screen abnormal
- Blood cultures and CSF culture/PCR during acute infection with serogrouping
- Immunoglobulins and vaccine responses to exclude antibody deficiency
- Properdin level (X-linked) if alternative pathway low
Management
- Suspect complement deficiency after recurrent, familial or unusual-serogroup Neisseria infection
- Treat acute meningococcal disease promptly with empirical ceftriaxone
- Screen with CH50 and AP50 — an absent CH50 points to classical/terminal defects, absent AP50 to alternative pathway
- Confirm the specific component with individual assays
- Vaccinate against meningococcus (ACWY and B), pneumococcus and Haemophilus influenzae type b
- Start long-term antibiotic prophylaxis in terminal complement deficiency
- Advise prompt assessment and early antibiotics for any febrile illness
- Screen family members and refer to clinical immunology
Drugs & doses
Ceftriaxone — 2 g IV every 12 hours for acute meningococcal disease
Phenoxymethylpenicillin — 250-500 mg orally twice daily for long-term prophylaxis
Meningococcal ACWY conjugate vaccine and meningococcal B vaccine — per schedule
Benzylpenicillin — 1.2 g IM pre-hospital if meningococcal disease suspected with delay to hospital
Disposition
Refer to clinical immunology for confirmation, vaccination and prophylaxis; admit acute invasive infection.
Complications & pitfalls
- Recurrent invasive meningococcal disease
- Meningitis and septic shock
- Delay to diagnosis due to normal routine immunology
- Incomplete vaccine protection against non-vaccine serogroups
- Transmission risk and family cases
Exam pearls
- Measure both CH50 and AP50 — a defect may only show in one pathway
- Terminal complement deficiency presents with recurrent meningococcaemia, often milder and with rare serogroups
- Vaccination and antibiotic prophylaxis dramatically reduce infection risk
- Screen and counsel family members, as many defects are inherited
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.